• Noora Rouvinen-Lagerström, Jari Lahti, Hannu Alho, Leena Kovanen, Mauri Aalto, Timo Partonen, Kaisa Silander, David Sinclair, Katri Räikkönen, Johan G Eriksson, Aarno Palotie, Seppo Koskinen, and Sirkku T Saarikoski.
• Ministry of Social Affairs and Health, Department of Occupational Safety and Health, PO Box 33, FI-00023 Government, Finland.
• Alcohol Alcohol. 2013 Sep 1; 48 (5): 519-25.

AimsThe molecular epidemiological studies on the association of the opioid receptor µ-1 (OPRM1) polymorphism A118G (Asn40Asp, rs1799971) and alcohol use disorders have given conflicting results. The aim of this study was to test the possible association of A118G polymorphism and alcohol use disorders and alcohol consumption in three large cohort-based study samples.MethodsThe association between the OPRM1 A118G (Asn40Asp, rs1799971) polymorphism and alcohol use disorders and alcohol consumption was analyzed using three different population-based samples: (a) a Finnish cohort study, Health 2000, with 503 participants having a DSM-IV diagnosis for alcohol dependence and/or alcohol abuse and 506 age- and sex-matched controls; (b) a Finnish cohort study, FINRISK (n = 2360) and (c) the Helsinki Birth Cohort Study (n = 1384). The latter two populations lacked diagnosis-based phenotypes, but included detailed information on alcohol consumption.ResultsWe found no statistically significant differences in genotypic or allelic distribution between controls and subjects with alcohol dependence or abuse diagnoses. Likewise no significant effects were observed between the A118G genotype and alcohol consumption.ConclusionThese results suggest that A118G (Asn40Asp) polymorphism may not have a major effect on the development of alcohol use disorders at least in the Finnish population.

23 keywords...

hide…